MaliTuberculosis profile
Population  2016 18 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.4 (0.83–2.1) 7.7 (4.6–11)
Mortality (HIV+TB only) 0.43 (0.28–0.61) 2.4 (1.5–3.4)
Incidence  (includes HIV+TB) 10 (6.6–14) 56 (37–79)
Incidence (HIV+TB only) 1.4 (0.9–2) 7.8 (5–11)
Incidence (MDR/RR-TB)** 0.38 (0.1–0.66) 2.1 (0.58–3.6)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.44 (0.27–0.61) 3.4 (2.1–4.7) 3.8 (2.4–5.3)
Males 0.51 (0.31–0.7) 5.7 (3.5–7.9) 6.2 (3.8–8.6)
Total 0.95 (0.59–1.3) 9.1 (5.6–13) 10 (6.6–14)
TB case notifications, 2016  
Total cases notified 7 038
Total new and relapse 6 776
          - % tested with rapid diagnostics at time of diagnosis 2%
          - % with known HIV status 59%
          - % pulmonary 81%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 68% (48–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.19 (0.1–0.29)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 478 12%
          - on antiretroviral therapy 456 95%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  230
(70–400)
Estimated % of TB cases with MDR/RR-TB 2.6% (0.1–5.1) 18% (0.1–36)  
% notified tested for rifampicin resistance 13% 30% 1 036
MDR/RR-TB cases tested for resistance to second-line drugs   6
Laboratory-confirmed cases MDR/RR-TB: 386, XDR-TB: 3
Patients started on treatment **** MDR/RR-TB: 27, XDR-TB: 2
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 77% 6 732
Previously treated cases, excluding relapse, registered in 2015 75% 283
HIV-positive TB cases registered in 2015 68% 523
MDR/RR-TB cases started on second-line treatment in 2014 75% 12
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 36%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
6% (5.5–6.6)
TB financing, 2017  
National TB budget (US$ millions) 6.5
Funding source: 22% domestic, 78% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-05-24 Data: www.who.int/tb/data